Amphastar Pharmaceuticals Inc vs Vanguard Total International Bond Index Fund ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Vanguard Total International Bond Index Fund ETF trades at $47.93. Which is the better fit depends on your goals.
| AMPH | BNDX | |
|---|---|---|
Market Cap | $863.95M | — |
Sector | Health | — |
52-Week High | $30.81 | $49.91 |
52-Week Low | $16.87 | $47.57 |
Enterprise Value | $1.26B | — |
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
BNDX, the Vanguard Total International Bond ETF, trades at $47.95, up 0.13% on the day. The technical outlook is neutral overall, with bearish moving averages and neutral oscillators. Recent corporate actions include scheduled dividend payments in 2026. Market sentiment is influenced by global bond yield fluctuations and institutional trading activity, as seen with Apella Capital reducing its stake and Archer Investment Management increasing its holdings.
The outlook for BNDX is tied to international bond market dynamics, with opportunities from investor demand for yield but risks from inflation data and geopolitical tensions affecting Treasury yields. Key risks include interest rate uncertainty and oil price volatility, which could pressure bond performance. Institutional interest remains mixed, reflecting cautious optimism amid macroeconomic headwinds.
Trailing returns across standard periods
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →The fund employs an indexing investment approach designed to track the performance of the Bloomberg Global Aggregate ex-USD Float Adjusted RIC Capped Index (USD Hedged). This index provides a broad-based measure of the global, investment-grade, fixed-rate debt markets. It is non-diversified.
Read more on BNDX →